HUTCHMED Ltd (HCM) Form 6-K — Oct 21, 2026
HUTCHMED announced the closing of its exclusive license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate, granting GSK worldwide rights excluding Greater China. Under the deal, HUTCHMED expects to receive US$110 million upfront shortly and may earn up to US$1.185 billion in development, regulatory and commercial milestones, plus tiered royalties on net sales. HUTCHMED retains responsibility for the global Phase I program, with Phase Ia initiated in September 2026 in China and the US.
Key figures
- Trial phase
- Phase Ia
- Closing date
- 2026-10-21
- Trial nct id
- NCT07718581
- Announcement date
- 2026-09-03
- Royalty structure
- tiered royalties on annual net sales
- Upfront payment usd
- 110000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.